Treatment of neonatal jaundice with filtered sunlight in Nigerian neonates: study protocol of a non-inferiority, randomized controlled trial

Tina M Slusher, Bolajoko O Olusanya, Hendrik J Vreman, Ronald J Wong, Ann M Brearley, Yvonne E Vaucher, David K Stevenson, Tina M Slusher, Bolajoko O Olusanya, Hendrik J Vreman, Ronald J Wong, Ann M Brearley, Yvonne E Vaucher, David K Stevenson

Abstract

Background: Severe neonatal jaundice and its progression to kernicterus is a leading cause of death and disability among newborns in poorly-resourced countries, particularly in sub-Saharan Africa. The standard treatment for jaundice using conventional phototherapy (CPT) with electric artificial blue light sources is often hampered by the lack of (functional) CPT devices due either to financial constraints or erratic electrical power. In an attempt to make phototherapy (PT) more readily available for the treatment of pathologic jaundice in underserved tropical regions, we set out to test the hypothesis that filtered sunlight phototherapy (FS-PT), in which potentially harmful ultraviolet and infrared rays are appropriately screened, will be as efficacious as CPT.

Methods/design: This prospective, non-blinded randomized controlled non-inferiority trial seeks to enroll infants with elevated total serum/plasma bilirubin (TSB, defined as 3 mg/dl below the level recommended by the American Academy of Pediatrics for high-risk infants requiring PT) who will be randomly and equally assigned to receive FS-PT or CPT for a total of 616 days at an inner-city maternity hospital in Lagos, Nigeria. Two FS-PT canopies with pre-tested films will be used. One canopy with a film that transmits roughly 33% blue light (wavelength range: 400 to 520 nm) will be used during sunny periods of a day. Another canopy with a film that transmits about 79% blue light will be used during overcast periods of the day. The infants will be moved from one canopy to the other as needed during the day with the goal of keeping the blue light irradiance level above 8 μW/cm²/nm.

Primary outcome: FS-PT will be as efficacious as CPT in reducing the rate of rise in bilirubin levels. Secondary outcome: The number of infants requiring exchange transfusion under FS-PT will not be more than those under CPT.

Conclusion: This novel study offers the prospect of an effective treatment for infants at risk of severe neonatal jaundice and avoidable exchange transfusion in poorly-resourced settings without access to (reliable) CPT in the tropics.

Trial registration: ClinicalTrials.gov Identifier: NCT01434810.

Figures

Figure 1
Figure 1
Filtered sunlight canopies. A: Experimental filtered sunlight canopy with a baby doll; B: Baby placed under a filtered sunlight canopy in an open lawn in a primary care setting; C: Mother-infant pairs with health workers under a group filtered sunlight canopy in a hospital setting.
Figure 2
Figure 2
Enrolment flow chart. CPT, conventional phototherapy; FS-PT, filtered sunlight phototherapy; TcB, transcutaneous bilirubin; TSB, total serum/plasma bilirubin.

References

    1. Escobar GJ, Greene JD, Hulac P, Kincannon E, Bischoff K, Gardner MN, Armstrong MA, France EK. Rehospitalisation after birth hospitalisation: patterns among infants of all gestations. Arch Dis Child. 2005;14:125–131.
    1. Tomashek KM, Crouse CJ, Iyasu S, Johnson CH, Flowers LM. A comparison of morbidity rates attributable to conditions originating in the perinatal period among newborns discharged from United States hospitals, 1989–90 and 1999–2000. Paediatr Perinat Epidemiol. 2006;14:24–34.
    1. The Young Infants Clinical Signs Study Group. Clinical signs that predict severe illness in children under age 2 months: a multicentre study. Lancet. 2008;14:135–142.
    1. Slusher TM, Olusanya BO. In: Care of the Jaundiced Neonate. Chapter 13. Stevenson DK, Maisels J, Watchko J, editor. New York, NY: McGraw-Hill; 2012. Neonatal jaundice in low- and middle-income countries; pp. 263–273.
    1. Mwaniki MK, Atieno M, Lawn JE, Newton CR. Long-term neurodevelopmental outcomes after intrauterine and neonatal insults: a systematic review. Lancet. 2012;14:445–452.
    1. Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med. 2008;14:920–928.
    1. Olusanya BO, Ezeaka VC, Ajayi-Obe EK, Mukhtar-Yola M, Ofovwe GE. Paediatricians’ perspectives on global health priorities for newborn care in a developing country: a national survey from Nigeria. BMC Int Health and Hum Rights. 2012;14:1–7.
    1. Effiong CE, Laditan AAO. Neonatal jaundice in Ibadan: a study of cases seen in the out-patients clinic. Nig J Paediatr. 1976;14:1–8.
    1. Slusher TM, Vreman HJ, McLaren DW, Lewison LJ, Brown AK, Stevenson DK. Glucose-6-phosphate dehydrogenase deficiency and carboxy-hemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants. J Pediatr. 1995;14:102–108.
    1. Owa JA, Osinaike AI. Neonatal morbidity and mortality in Nigeria. Indian J Pediatr. 1998;14:441–449.
    1. Ezeaka VC, Ogunbase AO, Awogbemi OT, Grange AO. Why our children die: a review of paediatric mortality in a tertiary centre in Lagos, Nigeria. Nig Qt J Hosp Med. 2003;14:17–21.
    1. Ogunlesi TA, Dedeke IO, Adekanmbi AF, Fetuga MB, Ogunfowora OB. The incidence and outcome of bilirubin encephalopathy in Nigeria: a bi-centre study. Niger J Med. 2007;14:354–359.
    1. English M, Ngama M, Musumba C, Wamola B, Bwika J, Mohammed S, Ahmed M, Mwarumba S, Ouma B, McHugh K, Newton C. Causes and outcome of young infant admissions to a Kenyan district hospital. Arch Dis Child. 2003;14:438–443.
    1. Duggan MB, Ogala W. Cerebral palsy in Nigeria: a report from Zaria. Ann Trop Paediatr. 1982;14:7–11.
    1. Izuora GI. Aetiology of mental retardation in Nigerian children around Enugu. Cent Afr J Med. 1985;14:13–16.
    1. Wolf MJ, Wolf B, Beunen G, Casaer P. Neurodevelopmental outcome at 1 year in Zimbabwean neonates with extreme hyperbilirubinaemia. Eur J Pediatr. 1999;14:111–114.
    1. Gordon AL, English M, Tumaini Dzombo J, Karisa M, Newton CR. Neurological and developmental outcome of neonatal jaundice and sepsis in rural Kenya. Trop Med Int Health. 2005;14:1114–1120.
    1. Olusanya BO, Somefun AO. Sensorineural hearing loss in infants with neonatal jaundice in a developing country: a community-based study. Ann Trop Paediatr. 2009;14:119–128.
    1. English M, Esamai F, Wasunna A, Were F, Ogutu B, Wamae A, Snow RW, Peshu N. Delivery of paediatric care at the first-referral level in Kenya. Lancet. 2004;14:1622–1629.
    1. Owa JA, Ogunlesi TA. Why we are still doing so many exchange blood transfusions for neonatal jaundice in Nigeria. World J Pediatr. 2009;14:51–55.
    1. Owa JA, Adebami OJ, Fadero FF, Slusher TM. Irradiance readings of phototherapy equipment: Nigeria. Indian J Pediatr. 2011;14:996–998.
    1. Cline BK, Vreman HJ, Faber K, Lou H, Donaldson KM, Amuabunosi E, Ofovwe G, Bhutani VK, Olusanya BO, Slusher TM. Phototherapy device effectiveness in Nigeria: irradiance assessment and potential for improvement. J Trop Pediatr. 2013;14:321–325.
    1. Cremer RJ, Perryman PW, Richards DH. Influence of light on the hyperbilirubinaemia of infants. Lancet. 1958;14:1094–1097.
    1. Salih FM. Can sunlight replace phototherapy units in the treatment of neonatal jaundice? An in vitro study. Photodermatol Photoimmunol Photomed. 2001;14:272–277.
    1. Vreman HJ, Slusher TM, Wong RJ, Schulz S, Olusanya BO, Stevenson DK. Evaluation of window-tinting films for sunlight phototherapy. J Trop Pediatr. 2013;14:496–501.
    1. National Institute for Health and Clinical Excellence. Neonatal jaundice. (Clinical guideline 98.) 2010. .
    1. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;14:297–316.
    1. Kaplan M, Slusher T, Renbaum P, Essiet DF, Pam S, Levy-Lahad E, Hammerman C. (TA)n UDP-glucuronosyltransferase 1A1 promoter polymorphism in Nigerian neonates. Pediatr Res. 2008;14:109–111.
    1. Beutler E, Blume KG, Kaplan JC, Lohr GW, Ramot B, Valentine WN. International Committee for Standardization in Haematology: recommended screening test for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Br J Haematol. 1979;14:465–467.
    1. World Health Organization. Thermal Protection of the Newborn: A Practical Guide. Geneva, Switzerland: WHO; 1997.

Source: PubMed

3
Subskrybuj